APOE genotype is a risk factor for neuropathy severity in diabetic patients

Neurology

Volumn 60, Issue 6, 2003, Pages 1022-1024

  Bedlack, R S ^a   Edelman, D ^a,b   Gibbs III, J W ^a   Kelling, D ^b   Strittmatter, W ^a   Saunders, A M ^c   Morgenlander, J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Carolinas Medical Center NorthEast   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISEASE DURATION; DISEASE SEVERITY; GENETIC RISK; GENOTYPE; HUMAN; LEG; MAJOR CLINICAL STUDY; MODEL; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM;

EID: 0037465780     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000056689.50682.94     Document Type: Article

References (10)

1. Thomas PK. Diabetic peripheral neuropathies: their cost to society and the value of knowledge of risk factors for development of interventions. Eur Neurol 1999;41S:35-43.
2. The diabetes control and complications trial group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
3. The diabetes control and complications trial group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA 1996;276:1409-1415.
4. Gautier J, Beressi J, Leblanc H, Vexiau P, Passa P. Are the implications of the diabetes control and complications trial (DCCT) feasible in daily clinical practice? Diabetes Metab 1996;22:415-419.
5. Meijer J, Links T, Smit A, Groothoff J, Eisma W. Evaluation of a screening and prevention program for diabetic foot complications. Prosthet Orthot Int 2001;25:132-138.
6. Tsuzuki S, Murano T, Watanabe H, Itoh Y, Miyashita Y, Shirai K. The examination of apoE phenotypes in diabetic patients with peripheral neuropathy [in Japanese]. Rinsho Byori 1998;46:829-833.
7. Bedlack RS, Strittmatter WJ, and Morgenlander JC. Apolipoprotein E and neuromuscular disease: a critical review of the literature. Arch Neurol 2000;57:1561-1565.
8. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-1472.
9. Richards B, Skoletsky J, Shuber AP, et al. Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs. Hum Mol Genet 1993;2:159-163.
10. Apfel S, Schwartz S, Adornato B, et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. JAMA 2000;284:2215-2221.